Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to the leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs, and sores or wounds on the lower limb that heal slowly, and poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age, and family history.
The intermittent claudication – drugs in development report provides an overview of the intermittent claudication pipeline landscape. It provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.
What are the key targets in the intermittent claudication pipeline products market?
The key targets in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase, and Hepatocyte Growth Factor.
Intermittent Claudication Pipeline Products by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the intermittent claudication pipeline products market?
The key mechanisms of action in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2 Activator, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase Activator, and Hepatocyte Growth Factor Activator.
Intermittent Claudication Pipeline Products by Mechanism of Action
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the intermittent claudication pipeline products market?
The key routes of administration in the intermittent claudication pipeline products market are intramuscular and sublingual.
Intermittent Claudication Pipeline Products by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the intermittent claudication pipeline products market?
The different molecule types in the intermittent claudication pipeline products market are gene therapy, cell therapy, and small molecule.
Intermittent Claudication Pipeline Products by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the intermittent claudication pipeline products market?
The major companies in the intermittent claudication pipeline products market are G. Pohl-Boskamp GmbH & Co KG, Helixmith Co Ltd, ID Pharma Co Ltd, and Pluristem Therapeutics Inc.
Intermittent Claudication Pipeline Products by Companies
To know more about major companies, download a free report sample
Market Report Scope
Key targets | Fibroblast Growth Factor 2, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase, and Hepatocyte Growth Factor |
Key mechanism of action | Fibroblast Growth Factor 2 Activator, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase Activator, and Hepatocyte Growth Factor Activator |
Key routes of administration | Intramuscular and Sublingual |
Molecule type | Gene Therapy, Cell Therapy, and Small Molecule |
Major companies | G. Pohl-Boskamp GmbH & Co KG, Helixmith Co Ltd, ID Pharma Co Ltd, and Pluristem Therapeutics Inc. |
Scope
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in intermittent claudication (cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates intermittent claudication (cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for intermittent claudication (cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the intermittent claudication pipeline products market?
The key targets in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase, and Hepatocyte Growth Factor.
-
What are the key mechanisms of action in the intermittent claudication pipeline products market?
The key mechanisms of action in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2 Activator, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase Activator, and Hepatocyte Growth Factor Activator.
-
What are the key routes of administration in the intermittent claudication pipeline products market?
The key routes of administration in the intermittent claudication pipeline products market are intramuscular and sublingual.
-
What are the different molecule types in the intermittent claudication pipeline products market?
The different molecule types in the intermittent claudication pipeline products market are gene therapy, cell therapy, and small molecule.
-
Which are the major companies in the intermittent claudication pipeline products market?
The major companies in the intermittent claudication pipeline products market are G. Pohl-Boskamp GmbH & Co KG, Helixmith Co Ltd, ID Pharma Co Ltd, and Pluristem Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.